MiMedx Pivots to Surgery and Sanara Acquisition as Wound Care Struggles
Read source articleWhat happened
At the Canaccord Genuity MedTech Conference, MiMedx CFO Doug Rice revealed that the company's core wound care franchise is under significant pressure, with third-quarter net sales reported at $62 million, a sharp decline from the $100 million+ quarterly run rate seen in 2025. Management is now betting on growth in its surgical segment and the pending acquisition of Sanara MedTech to offset the deterioration, marking a strategic shift toward diversification. This aligns with the earlier warning in the 10-K that the CY2026 Medicare skin-substitute reimbursement reset to a flat $127.14/cm² cap would be a headwind to Wound sales and profitability, and the Q3 figure suggests the impact is more severe than initially guided. The acquisition of Sanara MedTech, not mentioned in the latest DeepValue report, adds a complementary wound and surgical portfolio, but integration and synergy realization remain unproven. Investors must now assess whether the combined entity can stabilize revenue and margins, or if the wound care franchise continues to bleed.
Implication
The reported $62 million Q3 net sales are well below the $85-90 million implied by the 2026 guidance of $340-360 million, indicating that the Medicare reimbursement reset is causing a steeper volume and pricing decline than management initially projected. The shift toward surgical growth and the Sanara MedTech acquisition are rational defensive moves, but acquisitions often carry integration risk and may dilute near-term earnings, especially if funded with cash or debt. The master report's base case of $4.60 and bear case of $3.00 now appear more likely, and the stock's current valuation at 5.7x EV/EBITDA on trailing numbers may not hold if EBITDA falls. Investors should await quarterly details on the Sanara deal structure, synergy targets, and any signs of wound care stabilization before committing capital. Until then, a cautious stance is prudent, with the attractive entry potentially lowered to below $3.50.
Thesis delta
The previous thesis was a WAIT, predicated on waiting for Q1-Q2 2026 evidence of stabilization under the new reimbursement rules. The new information shows Q3 2026 net sales of only $62 million, far below the guided run-rate, indicating the wound care decline is deeper than anticipated. Additionally, the pending acquisition of Sanara MedTech introduces a new variable that could either bolster the portfolio or distract management and strain finances. Therefore, the thesis shifts to a more cautious outlook, with the bear case gaining probability and a potential downgrade to AVOID if the acquisition terms are unfavorable or wound care continues to deteriorate.
Confidence
medium